RxDoctor Payments Data

Jesi Ramone

Internal Medicine · Brooklyn, NYNPI 1407819907

Payments from drug & device makers

$626,825in general payments, 2019–2025

Across 1,002 payments — averaging $625.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$245K
  • AbbVie$181K
  • Gilead$147K
  • Janssen Products, LP$29K
  • Merck$21K
  • Theratechnologies Inc.$2K
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$42,4257%
  • Speaking & faculty fees$463,32474%
  • Travel & lodging$94,19115%
  • Food & beverage$26,6854%
  • Education$2010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$626,825 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala197$819,267
DovatoDolutegravir Sodium/Lamivudine164$510,373
CabenuvaCabotegravir/Rilpivirine63$409,529
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf80$396,018
TriumeqAbacavir/Dolutegravir/Lamivudi43$197,928
JanuviaSitagliptin Phosphate103$122,582
JulucaDolutegravir/Rilpivirine25$110,863
JardianceEmpagliflozin67$86,329
GenvoyaElviteg/Cob/Emtri/Tenof Alafen14$68,077
OdefseyEmtricitab/Rilpiviri/Tenof Ala18$64,059
DescovyEmtricitabine/Tenofov Alafenam23$47,077
TivicayDolutegravir Sodium16$34,687
LinzessLinaclotide38$23,629
OzempicSemaglutide16$14,488
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$11,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Cabenuva, Triumeq, Juluca, Tivicay$245,202$1,263,381311 claims
GileadBiktarvy, Genvoya, Descovy$146,833$934,421234 claims
Janssen Products, LPSymtuza$29,221$396,01880 claims
MerckJanuvia$21,261$122,582103 claims
Boehringer IngelheimJardiance, Spiriva Respimat$29$92,07678 claims
AbbVieLinzess$181,462$23,62938 claims
GSKIncruse Ellipta$23$6,49319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →